AstraZeneca PLC (AZN) Enterprise Value (EV): $304.88B
The enterprise value (EV) for AstraZeneca PLC (AZN) is $304.88B as of Friday, June 12, 2026.
AZN Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$304.88B
AZN Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| AstraZeneca PLC (AZN) | $282.69B | $304.88B |
| Merck & Co., Inc. (MRK) | $298.29B | $299.33B |
| UnitedHealth Group Incorporated (UNH) | $368.30B | $354.42B |
| Amgen Inc. (AMGN) | $191.09B | $221.57B |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | $248.87B |
| AbbVie Inc. (ABBV) | $397.12B | $470.64B |
| Gilead Sciences, Inc. (GILD) | $156.28B | $169.72B |
| Abbott Laboratories (ABT) | $156.15B | $225.43B |
| Pfizer Inc. (PFE) | $149.18B | $207.77B |
| Intuitive Surgical, Inc. (ISRG) | $146.23B | $199.07B |
Enterprise Value Calculation
Market Cap
$282.69B
Total Debt
$27.90B
Cash
$5.71B
Enterprise Value
$304.88B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
AstraZeneca PLC Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for AstraZeneca PLC (AZN)?
- The enterprise value (EV) for AZN stock is $304.88B.
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot